妊娠期糖尿病的异质性与不良妊娠结局风险:一项队列研究
研究前瞻性纳入2050名行75g口服葡萄糖耐量试验的孕妇,分为血糖正常组(936例)、单纯空腹血糖受损的妊娠期空腹血糖受损组(378例)和单纯餐后血糖耐受受损的妊娠期餐后血糖受损组(736例),评估胰岛素生理及妊娠结局。结果显示妊娠期空腹血糖受损组胰岛素抵抗更重,妊娠期餐后血糖受损组β细胞功能更差,两亚型不良妊娠结局风险不同。
要点
- 妊娠期空腹血糖受损组胰岛素抵抗重于妊娠期餐后血糖受损组(HOMA-IR 3.11 vs 2.25)。
- 妊娠期餐后血糖受损组β细胞功能差于妊娠期空腹血糖受损组(C肽 2.00 vs 2.26 ng/mL)。
- 妊娠期空腹血糖受损组与巨大儿和孕期增重过多关联更强,妊娠期餐后血糖受损组与早产和新生儿脑损伤关联更强。
核心结论
- 妊娠期糖尿病具有不同的胰岛素生理特征,各表型的妊娠结局存在差异,为风险分层和差异化治疗策略提供了证据。
研究设计与样本
- 前瞻性队列研究,共纳入2050名行75g口服葡萄糖耐量试验并随访至分娩的孕妇,分为血糖正常组(n=936)、妊娠期空腹血糖受损组(n=378)和妊娠期餐后血糖受损组(n=736)。
- 于孕中期采集空腹血样测定C肽和胰岛素浓度,采用稳态模型评估(HOMA)和定量胰岛素敏感性检查指数(QUICKI)评估胰岛素生理,记录母婴结局。
主要发现
- 妊娠期空腹血糖受损组较妊娠期餐后血糖受损组胰岛素抵抗更重(HOMA-IR 3.11 vs 2.25,QUICKI-C肽 0.94 vs 1.03,均P<.01)。
- 妊娠期餐后血糖受损组较妊娠期空腹血糖受损组β细胞功能更差(C肽 2.00 vs 2.26 ng/mL,P<.05)。
- 妊娠期空腹血糖受损组与孕期增重过多(RR 1.62;95%CI 1.18-2.23)和大于胎龄儿(RR 1.45;95%CI 1.03-2.03)的关联强于妊娠期餐后血糖受损组。
- 妊娠期餐后血糖受损组新生儿脑损伤风险升高(RR 2.03;95%CI 1.04-4.09),妊娠期空腹血糖受损组未见升高(P=.439)。
- 妊娠期餐后血糖受损组与早产风险的关联强于妊娠期空腹血糖受损组(RR 1.80;95%CI 1.02-3.36)。
临床怎么用
- 原文结论指出这些发现为妊娠期糖尿病的风险分层和差异化治疗策略提供了证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetes is increasingly recognized as a heterogeneous disease, with clinical characteristics and outcome risks varying across different phenotypes. Evidence on heterogeneity of gestational diabetes (GDM) is yet to be provided. OBJECTIVE: To investigate the insulin physiology and pregnancy outcomes of GDM phenotypes characterized by fasting hyperglycemia or postload hyperglycemia. METHODS: A total of 2050 women who underwent a 75-g oral glucose tolerance test were prospectively recruited and followed until delivery. Women were categorized into normoglycemia (NGT, n = 936), isolated impaired fasting glucose (gestational-IFG, n = 378), and isolated impaired postload glucose tolerance (gestational-IGT, n = 736) groups. Fasting blood samples at mid-pregnancy were collected to measure C-peptide and insulin concentrations. Homeostasis model assessment (HOMA) and quantitative insulin sensitivity check index (QUICKI) were used to evaluate insulin physiology. Maternal and neonatal outcomes were recorded. RESULTS: Gestational-IFG had greater insulin resistance (HOMA-IR 3.11 vs 2.25, QUICKI-C-peptide 0.94 vs 1.03, both P < .01), and gestational-IGT had worse β-cell function (C-peptide 2.00 vs 2.26 ng/mL, P < .05), when compared to one another. Gestational-IFG was more strongly associated with excessive gestational weight gain (risk ratio [RR] 1.62; 95% CI, 1.18-2.23) and large-for-gestational-age infants (RR 1.45; 95% CI, 1.03-2.03) than gestational-IGT. The risk for neonatal brain injury was increased in gestational-IGT (RR 2.03; 95% CI, 1.04-4.09), but not in gestational-IFG (P = .439). Gestational-IGT showed a stronger association with the risk of preterm birth compared to gestational-IFG (RR 1.80; 95% CI, 1.02-3.36). CONCLUSION: GDM exhibits distinct insulin physiology profiles. Pregnancy outcome varies between each phenotype. These findings provide evidence on risk stratification and diverse strategies for the treatment of GDM.
引用
- Gong Y, Wang Q, Chen S, et al. Heterogeneity of Gestational Diabetes and Risk for Adverse Pregnancy Outcome: A Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 39446494. doi:10.1210/clinem/dgae754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。